BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW

BIOVIE INC.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026

$1.37+0.17 (+14.17%)

Close on Oct 19, 2026

Market cap: $10.86M
P/E (TTM): –
Dividend yield: –

BIOVIE INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q4 2026 2026-06-30	Q3 2026 2026-03-31	Q2 2026 2025-12-31	Q1 2026 2025-09-30	Q4 2025 2025-06-30	Q3 2025 2025-03-31	Q2 2025 2024-12-31	Q1 2025 2024-09-30	Q4 2024 2024-06-30	Q3 2024 2024-03-31	Q2 2024 2023-12-31	Q1 2024 2023-09-30	Q4 2023 2023-06-30	Q3 2023 2023-03-31	Q2 2023 2022-12-31	Q1 2023 2022-09-30	Q4 2022 2022-06-30	Q3 2022 2022-03-31	Q2 2022 2021-12-31	Q1 2022 2021-09-30	Q4 2021 2021-06-30	Q3 2021 2021-03-31	Q2 2021 2020-12-31	Q1 2021 2020-09-30	Q4 2020 2020-06-30	Q3 2020 2020-03-31	Q2 2020 2019-12-31	Q1 2020 2019-09-30	Q4 2019 2019-06-30	Q1 2019 2018-12-31	Q4 2018 2018-06-30	Q3 2018 2018-03-31	Q2 2018 2017-12-31	Q1 2018 2017-09-30	Q4 2017 2017-06-30	Q3 2017 2017-03-31	Q2 2017 2016-12-31	Q1 2017 2016-09-30	Q4 2016 2016-06-30	Q3 2016 2016-03-31
Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–
Gross Profit	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–
Research & Development	3.58	3.18	4.27	2.94	1.22	1.34	4.70	1.99	2.05	5.70	6.47	8.88	8.30	11	7.03	6.77	5.87	3.58	4.71	3.09	0.53	0.79	0.94	0.10	0.15	0.35	0.35	0.34	0.28	0.40	0.10	0.05	0.19	0.04	0.09	0.12	0.13	0.13	–	–
Selling, General & Admin	–	–	–	2.29	2.38	1.59	2.53	2.07	2.68	1.97	2.25	1.94	2.62	2.52	4.40	2.01	3.36	2.11	1.89	2.40	0.38	2.15	2.07	0.23	0.37	0.29	0.31	0.31	0.32	0.48	0.37	0.59	0.25	0.04	0.03	0.03	0.01	0.00	0.01	0.00
General & Administrative	2.13	2.15	1.94	–	2.38	1.59	2.53	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	5.72	5.39	6.26	5.28	3.66	2.99	7.29	4.12	4.79	7.73	8.78	11	11	14	11	8.83	9.29	5.75	6.67	5.55	132	3.00	3.06	0.39	0.58	0.70	0.71	0.71	0.66	0.99	0.52	0.69	0.49	0.66	0.44	0.40	0.36	0.35	0.27	0.06
Operating Income	-5.72	-5.39	-6.26	-5.28	-3.66	-2.99	-7.29	-4.12	-4.79	-7.73	-8.78	-11	-11	-14	-11	-8.83	-9.29	-5.75	-6.67	-5.55	-132	-3.00	-3.06	-0.39	-0.58	-0.70	-0.71	-0.71	-0.66	-0.99	-0.52	-0.69	-0.49	-0.66	-0.44	-0.40	-0.36	-0.35	-0.27	-0.06
Interest Expense	0.00	0.01	0.01	0.00	0.00	0.00	0.07	0.26	0.44	0.63	0.82	1.00	1.11	1.08	1.05	1.06	0.93	0.92	0.32	0.00	0	0	0.00	0.56	1.24	0.03	0.02	3.48	0.00	0.00	0.03	0.00	0.01	0.00	–	–	–	–	–	–
Interest & Investment Income	0.08	0.12	0.20	0.20	0.18	0.20	0.25	0.22	0.27	0.18	0.22	0.46	0.26	0.18	0.08	0.04	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0	0.00	0.00	0.00	0.00	0.00	0	0	0.00	0	0.00	0	0.00	0.00	0.00
Other Non-Operating Income	0.07	0.12	0.19	0.20	0.17	0.20	0.18	-0.03	-0.15	-0.34	0.38	0.17	1.86	-1.27	-4.19	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–
Net Income incl. Noncontrolling Interests	-5.65	-5.27	-6.07	-5.09	-3.49	-2.79	-7.11	-4.15	-4.94	-8.07	-8.40	-11	-9.11	-15	-16	-10	-8.09	-7.04	-5.41	-5.54	–	-2.99	–	7.33	-19	-0.37	6.67	-3.82	-0.66	-0.94	-0.56	-0.69	-0.50	-0.66	–	–	–	–	–	–
Net Income	-5.65	-5.27	-6.07	-5.09	-3.49	-2.79	-7.11	-4.15	-4.94	-8.07	-8.40	-11	-9.11	-15	-16	-10	-8.09	-7.04	-5.41	-5.54	-132	-2.99	-3.06	7.33	-19	-0.37	6.67	-3.82	–	–	-0.58	-0.69	-0.50	-0.66	-0.44	-0.18	-0.36	-0.35	-0.27	-0.06
Net Income to Common	–	–	–	–	–	–	–	–	-4.94	-8.95	-8.40	-11	-9.11	-15	-16	-10	-8.09	-7.04	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.71	-0.70	-0.77	-0.98	–	-1.51	-4.55	-7.00	–	-2.00	-2.20	-2.92	–	-0.43	-0.50	-0.38	-0.32	-0.28	-0.22	-0.23	-8.32	-0.22	-0.22	-7.75	-3.68	-0.07	1.29	-5.06	–	-0.40	-0.73	-1.25	-1.25	-1.25	–	0.00	0.00	0.00	–	0.00
EPS (Diluted)(per share)	-0.71	-0.70	-0.77	-0.98	–	-1.51	-4.55	-7.00	–	-2.00	-2.20	-2.92	–	-0.43	-0.50	-0.38	-0.32	-0.28	-0.22	-0.23	-8.32	-0.22	-0.22	-7.75	-3.68	-0.07	1.29	-5.06	–	-0.40	-0.73	-1.25	-1.25	-1.25	–	0.00	0.00	0.00	–	0.00
Shares Outstanding (Basic, Weighted)(shares)	7.92	7.54	7.92	5.21	1.86	1.85	1.57	0.64	–	4.48	3.82	3.67	–	35	31	27	25	25	25	24	16	14	14	5.97	5.20	5.20	5.18	4.13	2.67	2.50	0.78	0.78	0.76	0.75	0.73	0.73	0.70	0.70	0.70	0.70
Shares Outstanding (Diluted, Weighted)(shares)	7.92	7.54	7.92	5.21	1.86	1.85	1.57	0.64	–	4.48	3.82	3.67	–	35	31	27	25	25	25	24	16	14	14	5.97	5.20	5.20	5.18	4.13	2.67	2.50	0.78	0.78	0.76	0.75	0.73	0.73	0.70	0.70	0.70	0.70
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-5.69	–	–	–	-2.94	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -150.8%

Financial strength

Current ratio: 3.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 236.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.06
Dividend yield: –